All News
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis
Qin and colleagues have published in Arthritis & Rheumatology that 40% of people will be affected by symptomatic osteoarthritis in at least one hand. (Citation source: http://buff.ly/2qTUscZ)
Read Article
Calcium Supplements and Cardiovascular Risk
Dr. Nancy Lane answers questions about the intake of Calcium, Vitamin D and the cardiovascular risk of supplemental calcium.
Read Article
The RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read Article
Tofacitinib Effective in Ulcerative Colitis
Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).
Read Article
NEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read Article
The RheumNow Week in Review – 28 April 2017
Dr. Jack Cush reviews the news from the last week on RheumNow.com - from the ACR SOTA 2017 meeting in Chicago:
Read Article
Pregnancy Flares in RA and Spondylitis
Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission. Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.
Read Article
EULAR/EFORT Taskforce on the Management of Fragility Fractures
The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.
Read Article
Consensus on OP Drug Holidays
Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.
Read Article
FDA Approves Renflexis as Second Infliximab Biosimilar
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Read Article
The RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Paradoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
Read Article
Anti-IL-23 Therapy Effective in Crohn's Disease
Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.
Read Article
The Cost of Not Taking Medicine
The NY Times points out "there is is an out-of-control epidemic in the United States that costs more and affects more people than any disease Americans currently worry about. It’s called nonadherence to prescribed medications, and it is — potentially, at least — 100 percent preventable by the very individuals it afflicts.
Read Article
The RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Read Article
Acute Steroid Use Comes with Risk
Steroids are known for their acute therpeutic wonders and chronic hazards. Hence most practitioners are comfortable using short term, limited dose corticosteroids for a variety of ailments.
Read Article
Celecoxib Plus PPI Preferred in High Risk Patients
When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.
Read Article
Hydroxychloroquine Underperforms in a Cutaneous Lupus Trial
Hydroxychloroquine has become a mainstay in the treatement of patients with systemic lupus erythematosus (SLE) with proven efficacy in managing many domains of lupus, including skin, joint, and other autoimmune features.
Read Article
Biologic Safety Holds Up in RA
An updated systematic literature review has provided reassuring evidence regarding the increasing safety of biologic disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA), European researchers reported.
Read Article
